Pain biotech Latigo eyes up to $150M raise following Vertex's landmark FDA nod

Kyle LaHucik

Senior Reporter

Latigo Biotherapeutics, a non-opioid pain biotech looking to ride the waves created by Vertex Pharmaceuticals’ pain drug approval last month, is targeting up to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pain biotech Latigo eyes up to $150M raise following Vertex's landmark FDA nod

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

BridgeBio’s heart disease drug Attruby sails past prescription estimates

Can amylin drugs take over from GLP-1s in obesity? Partnerless Zealand thinks so

In single case, spinal muscular atrophy drug given before birth spared baby of genetic disease symptoms

How Keymed steered the China-to-US NewCo model in biotech

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Pain biotech Lati­go eyes up to $150M raise fol­low­ing Ver­tex's land­mark FDA nod

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Bridge­Bio’s heart dis­ease drug At­tru­by sails past pre­scrip­tion es­ti­mates

Can amylin drugs take over from GLP-1s in obe­si­ty? Part­ner­less Zealand thinks so

In sin­gle case, spinal mus­cu­lar at­ro­phy drug giv­en be­fore birth spared ba­by of ge­net­ic dis­ease symp­toms

How Keymed steered the Chi­na-to-US New­Co mod­el in biotech

Will CRISPR mat­ter?

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

Pain biotech Latigo eyes up to $150M raise following Vertex's landmark FDA nod

BridgeBio’s heart disease drug Attruby sails past prescription estimates

Can amylin drugs take over from GLP-1s in obesity? Partnerless Zealand thinks so

In single case, spinal muscular atrophy drug given before birth spared baby of genetic disease symptoms

How Keymed steered the China-to-US NewCo model in biotech

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence